+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Liquid Biopsy Market, Size, Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis

  • PDF Icon

    Report

  • 180 Pages
  • September 2022
  • Region: United States
  • Renub Research
  • ID: 5654358

United States Liquid Biopsy Market reached US$ 305.4 Million in 2021

United States Liquid Biopsy Market is expected to reach US$ 803.8 Million by 2027. Liquid biopsy is the molecular examination of nucleic acids, subcellular structures, particularly exosomes, and, in the case of cancer, circulating tumor cells in bodily fluids. Liquid biopsy has been the subject of intense research over the last ten years to develop a less invasive and more precise individualized therapy. Furthermore, due to its sophisticated nature, which includes a short turnaround time and feasibility and the capacity to do early cancer screening, liquid biopsies are becoming more popular in the United States.



United States Liquid Biopsy Market Size is expected to expand at a CAGR of 17.50% during 2021-2027

The liquid biopsy methods are minimally invasive and cost-effective in the United States. As a result, they are a popular alternative for cancer diagnosis among Americans. Other essential driving factors influencing the US liquid biopsy market in the projected period include an increase in patient demand for non-invasive treatment procedures and the number of cancer patients. However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.

How COVID-19 Affected United States Liquid Biopsy Industry

The coronavirus outbreak damaged the US biopsy diagnostics centers, hospitals, supply chains, and clinical trials. As a result, cancer diagnoses were being delayed since clinics had been closed since the start of the COVID-19 pandemic, and diagnosis and screening services were growing slower. In addition, cancer patients had numerous obstacles outside of the pandemic, including increased susceptibility to severe infection and disruptions in treatment or routine medical care. According to our estimates, the United States Liquid Biopsy Market reached US$ 305.4 Million in 2021 post recovery from the pandemic scenario.

Lung Cancer Accounts for The Dominant Market Share in The Forecast Period

The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer. Lung cancer is expected to have the largest market share during the projection period. According to the American Cancer Society, non-small-cell lung cancer, the most frequent kind of lung cancer in the United States, will be diagnosed in 235,760 persons in 2021. Lung cancer affects one in every 17 men and one in every 15 women at some point in their lives.

By Product, Assay Kits Holds the Largest Market Share

The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services. The kits and consumables are expected to have the most significant market share during the projection period. In the projection period, demand for kits and consumables will be driven by the ability to repeat sampling for liquid biopsy and their convenience and affordability.

Circulating Tumor Cells Maintains Their Dominance

The liquid biopsy market in the United States is classified into Circulating tumor cells (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs), and Other biomarkers based on the circulating biomarker (cell-free DNA, etc.). Circular tumor cells are expected to maintain their dominance throughout the predicted period. The market demand for Circulating tumor DNA is being driven by the rising frequency of cancer and the introduction of ctDNA-based liquid biopsy analysis, which can evaluate prognosis and tumor progression (ctDNA).

Other Segment Covered in Our Report Includes the Following

  • Based on clinical application, the market has been segmented into monitoring, prognosis, theranostics, and screening.
  • In addition, the market has been segmented into blood, urine, and others based on a sample.
  • Finally, based on application, the market has been segmented into molecular health monitoring, therapy selection for other meta cancer, and therapy selection for MBS.
  • The market has been segmented into hospitals and laboratories and government & academic research centers based on end-user.

Key Companies Insights

Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc, and Qiagen are among the important players profiled in our report. These market players in the United States contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.

The publisher's latest report “United States Liquid Biopsy Market, Forecast By Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and Others), By Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating tumor cell (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs) and Other biomarkers (cell free DNA,etc)), Clinical Application (Monitoring, Prognosis, Theranostics and Screening), Sample (Blood, Urine and Others), Application (Molecular Health Monitoring, Therapy Selection for Other Meta Cancer and Therapy Selection for MBS), End User (Hospitals and Laboratories and Government & Academic Research Centers), Companies (Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc and Qiagen)” provides a detailed analysis of United States Liquid Biopsy Industry.

By Cancer, the Market has been segmented into 5 viewpoints

1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Prostate Cancer
5. Others

By Product the Market has been segmented into 3 viewpoints

1. Kits & Consumables
2. Instruments
3. Services

By Circulating Biomarkers, the market has been segmented into 4 viewpoints

1. Circulating tumor cell (CTCs)
2. Circulating tumor DNA (ctDNA)
3. Extracellular vesicles (EVs)
4. Other biomarkers (cell free DNA,etc)

By Clinical Application the market has been segmented into 4 viewpoints

1. Monitoring
2. Prognosis
3. Theranostics
4. Screening

By Sample the market has been segmented into 3 viewpoints

1. Blood
2. Urine
3. Others

By Application, the market has been segmented into 3 viewpoints

1. Molecular Health Monitoring
2. Therapy Selection for Other Meta Cancer
3. Therapy Selection for MBS

By End User, the market has been segmented from 2 viewpoints

1. Hospitals and Laboratories
2. Government & Academic Research Centers

Company Insights

  • Overview
  • Product Portfolio
  • Financial Insight

Companies Covered

1. Thermo Fisher Scientific Inc
2. Roche Diagnostics
3. Bio-Rad Laboratories Inc
4. Biocept, Inc.
5. Biocartis
6. Myriad Genetics, Inc.
7. Exact Sciences (Genomic Health)
8. NeoGenomics Laboratories
9. Quest Diagnostic Inc
10. Qiagen

Frequently Asked Questions about the U.S. Liquid Biopsy Market

What is the estimated value of the U.S. Liquid Biopsy Market?

The U.S. Liquid Biopsy Market was estimated to be valued at $305.4 Million in 2021.

What is the growth rate of the U.S. Liquid Biopsy Market?

The growth rate of the U.S. Liquid Biopsy Market is 17.5%, with an estimated value of $803.8 Million by 2027.

What is the forecasted size of the U.S. Liquid Biopsy Market?

The U.S. Liquid Biopsy Market is estimated to be worth $803.8 Million by 2027.

Who are the key companies in the U.S. Liquid Biopsy Market?

Key companies in the U.S. Liquid Biopsy Market include Thermo Fisher Scientific Inc, Roche Diagnostics, Bio, Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., eoGeno Exact Sciences (Genomic Health), Nmics Laboratories and Quest Diagnostic Inc.

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Liquid Biopsy Market
6. Market Share - United States Liquid Biopsy
6.1 By Cancer
6.2 By Product
6.3 By Circulating Biomarkers
6.4 By Clinical Application
6.6 By Application
6.7 By End User
7. Cancer - United States Liquid Biopsy Market
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Prostate Cancer
7.6 Others
8. Product - United States Liquid Biopsy Market
8.1 Kits & Consumables
8.2 Instruments
8.3 Services
9. Circulating Biomarkers - United States Liquid Biopsy Market
9.1 Circulating tumor cell (CTCs)
9.2 Circulating tumor DNA (ctDNA)
9.3 Extracellular vesicles (EVs)
9.4 Other biomarkers (cell free DNA,etc)
10. Clinical Application - United States Liquid Biopsy Market
10.1 Monitoring
10.2 Prognosis
10.3 Theranostics
10.4 Screening
11. Sample - United States Liquid Biopsy Market
11.1 Blood
11.2 Urine
11.3 Others
12. Application - United States Liquid Biopsy Market
12.1 Molecular Health Monitoring
12.2 Therapy Selection for Other Meta Cancer
12.3 Therapy Selection for MBS
13. End User - United States Liquid Biopsy Market
13.1 Hospitals and Laboratories
13.2 Government & Academic Research Centers
14. Company Analysis
14.1 Thermo Fisher Scientific Inc
14.1.1 Overview
14.1.2 Product Portfolio
14.1.3 Financial Insight
14.2 Roche Diagnostics
14.2.1 Overview
14.2.2 Product Portfolio
14.2.3 Financial Insight
14.3 Bio-Rad Laboratories Inc
14.3.1 Overview
14.3.2 Product Portfolio
14.3.3 Financial Insight
14.4 Biocept, Inc.
14.4.1 Overview
14.4.2 Product Portfolio
14.4.3 Financial Insight
14.5 Biocartis
14.5.1 Overview
14.5.2 Product Portfolio
14.5.3 Financial Insight
14.6 Myriad Genetics, Inc
14.6.1 Overview
14.6.2 Product Portfolio
14.6.3 Financial Insight
14.7 Exact Sciences (Genomic Health)
14.7.1 Overview
14.7.2 Product Portfolio
14.7.3 Financial Insight
14.8 NeoGenomics Laboratories
14.8.1 Overview
14.8.2 Product Portfolio
14.8.3 Financial Insight
14.9 Quest Diagnostic Inc
14.9.1 Overview
14.9.2 Product Portfolio
14.9.3 Financial Insight
14.10 Qiagen
14.10.1 Overview
14.10.2 Product Portfolio
14.10.3 Financial Insight
List of Figures
Figure 01: United States - Liquid Biopsy Market (Million US$), 2017 - 2021
Figure 02: United States - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 03: United States - Lung Cancer Market (Million US$), 2017 - 2021
Figure 04: United States - Forecast for Lung Cancer Market (Million US$), 2022 - 2027
Figure 05: United States - Breast Cancer Market (Million US$), 2017 - 2021
Figure 06: United States - Forecast for Breast Cancer Market (Million US$), 2022 - 2027
Figure 07: United States - Colorectal Cancer Market (Million US$), 2017 - 2021
Figure 08: United States - Forecast for Colorectal Cancer Market (Million US$), 2022 - 2027
Figure 09: United States - Prostate Cancer Market (Million US$), 2017 - 2021
Figure 10: United States - Forecast for Prostate Cancer Market (Million US$), 2022 - 2027
Figure 11: United States - Others Market (Million US$), 2017 - 2021
Figure 12: United States - Forecast for Others Market (Million US$), 2022 - 2027
Figure 13: Product - Kits & Consumables Market (Million US$), 2017 - 2021
Figure 14: Product - Forecast for Kits & Consumables Market (Million US$), 2022 - 2027
Figure 15: Product - Instruments Market (Million US$), 2017 - 2021
Figure 16: Product - Forecast for Instruments Market (Million US$), 2022 - 2027
Figure 17: Product - Services Market (Million US$), 2017 - 2021
Figure 18: Product - Forecast for Services Market (Million US$), 2022 - 2027
Figure 19: Circulating Biomarkers - Circulating tumor cell (CTCs) Market (Million US$), 2017 - 2021
Figure 20: Circulating Biomarkers - Forecast for Circulating tumor cell (CTCs) Market (Million US$), 2022 - 2027
Figure 21: Circulating Biomarkers - Circulating tumor DNA (ctDNA) Market (Million US$), 2017 - 2021
Figure 22: Circulating Biomarkers - Forecast for Circulating tumor DNA (ctDNA) Market (Million US$), 2022 - 2027
Figure 23: Circulating Biomarkers - Extracellular vesicles (EVs) Market (Million US$), 2017 - 2021
Figure 24: Circulating Biomarkers - Forecast for Extracellular vesicles (EVs) Market (Million US$), 2022 - 2027
Figure 25: Circulating Biomarkers - Other biomarkers (cell free DNA,etc) Market (Million US$), 2017 - 2021
Figure 26: Circulating Biomarkers - Forecast for Other biomarkers (cell free DNA,etc) Market (Million US$), 2022 - 2027
Figure 27: Clinical Application - Monitoring Market (Million US$), 2017 - 2021
Figure 28: Clinical Application - Forecast for Monitoring Market (Million US$), 2022 - 2027
Figure 29: Clinical Application - Prognosis Market (Million US$), 2017 - 2021
Figure 30: Clinical Application - Forecast for Prognosis Market (Million US$), 2022 - 2027
Figure 31: Clinical Application - Theranostics Market (Million US$), 2017 - 2021
Figure 32: Clinical Application - Forecast for Theranostics Market (Million US$), 2022 - 2027
Figure 33: Clinical Application - Screening Market (Million US$), 2017 - 2021
Figure 34: Clinical Application - Forecast for Screening Market (Million US$), 2022 - 2027
Figure 35: Sample - Blood Market (Million US$), 2017 - 2021
Figure 36: Sample - Forecast for Blood Market (Million US$), 2022 - 2027
Figure 37: Sample - Urine Market (Million US$), 2017 - 2021
Figure 38: Sample - Forecast for Urine Market (Million US$), 2022 - 2027
Figure 39: Sample - Others Market (Million US$), 2017 - 2021
Figure 40: Sample - Forecast for Others Market (Million US$), 2022 - 2027
Figure 41: Application - Molecular Health Monitoring Market (Million US$), 2017 - 2021
Figure 42: Application - Forecast for Molecular Health Monitoring Market (Million US$), 2022 - 2027
Figure 43: Application - Therapy Selection for Other Meta Cancer Market (Million US$), 2017 - 2021
Figure 44: Application - Forecast for Therapy Selection for Other Meta Cancer Market (Million US$), 2022 - 2027
Figure 45: Application - Therapy Selection for MBS Market (Million US$), 2017 - 2021
Figure 46: Application - Forecast for Therapy Selection for MBS Market (Million US$), 2022 - 2027
Figure 47: End User - Hospitals and Laboratories Market (Million US$), 2017 - 2021
Figure 48: End User - Forecast for Hospitals and Laboratories Market (Million US$), 2022 - 2027
Figure 49: End User - Government & Academic Research Centers Market (Million US$), 2017 - 2021
Figure 50: End User - Forecast for Government & Academic Research Centers Market (Million US$), 2022 - 2027
Figure 51: Thermo Fisher Scientific Inc - Global Revenue (Million US$), 2017 - 2021
Figure 52: Thermo Fisher Scientific Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 53: Roche Diagnostics - Global Revenue (Million US$), 2017 - 2021
Figure 54: Roche Diagnostics - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 55: Bio-Rad Laboratories Inc - Global Revenue (Million US$), 2017 - 2021
Figure 56: Bio-Rad Laboratories Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 57: Biocept, Inc. - Global Revenue (Million US$), 2017 - 2021
Figure 58: Biocept, Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 59: Biocartis - Global Revenue (Million US$), 2017 - 2021
Figure 60: Biocartis - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 61: Myriad Genetics, Inc - Global Revenue (Million US$), 2017 - 2021
Figure 62: Myriad Genetics, Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 63: Exact Sciences (Genomic Health) - Global Revenue (Million US$), 2017 - 2021
Figure 64: Exact Sciences (Genomic Health) - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 65: NeoGenomics Laboratories - Global Revenue (Million US$), 2017 - 2021
Figure 66: NeoGenomics Laboratories - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 67: Quest Diagnostic Inc - Global Revenue (Million US$), 2017 - 2021
Figure 68: Quest Diagnostic Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 69: Qiagen - Global Revenue (Million US$), 2017 - 2021
Figure 70: Qiagen - Forecast for Global Revenue (Million US$), 2022 - 2027
List of Tables
Table 01: United States - Liquid Biopsy Market Share by Cancer (Percent), 2017 - 2021
Table 02: United States - Forecast for Liquid Biopsy Market Share by Cancer (Percent), 2022 - 2027
Table 03: United States - Liquid Biopsy Market Share by Product (Percent), 2017 - 2021
Table 04: United States - Forecast for Liquid Biopsy Market Share by Product (Percent), 2022 - 2027
Table 05: United States - Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2017 - 2021
Table 06: United States - Forecast for Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2022 - 2027
Table 07: United States - Liquid Biopsy Market Share by Clinical Application (Percent), 2017 - 2021
Table 08: United States - Forecast for Liquid Biopsy Market Share by Clinical Application (Percent), 2022 - 2027
Table 09: United States - Liquid Biopsy Market Share by Application (Percent), 2017 - 2021
Table 10: United States - Forecast for Liquid Biopsy Market Share by Application (Percent), 2022 - 2027
Table 11: United States - Liquid Biopsy Market Share by End User (Percent), 2017 - 2021
Table 12: United States - Forecast for Liquid Biopsy Market Share by End User (Percent), 2022 - 2027

Companies Mentioned

  • Thermo Fisher Scientific Inc
  • Roche Diagnostics
  • Bio-Rad Laboratories Inc
  • Biocept, Inc.
  • Biocartis
  • Myriad Genetics, Inc.
  • eoGeno Exact Sciences (Genomic Health)
  • Nmics Laboratories
  • Quest Diagnostic Inc
  • Qiagen

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...